The emerging role of deubiquitylating enzymes as therapeutic targets in cancer metabolism.
Ontology highlight
ABSTRACT: Cancer cells must rewire cellular metabolism to satisfy the unbridled proliferation, and metabolic reprogramming provides not only the advantage for cancer cell proliferation but also new targets for cancer treatment. However, the plasticity of the metabolic pathways makes them very difficult to target. Deubiquitylating enzymes (DUBs) are proteases that cleave ubiquitin from the substrate proteins and process ubiquitin precursors. While the molecular mechanisms are not fully understood, many DUBs have been shown to be involved in tumorigenesis and progression via controlling the dysregulated cancer metabolism, and consequently recognized as potential drug targets for cancer treatment. In this article, we summarized the significant progress in understanding the key roles of DUBs in cancer c
SUBMITTER: Tu R
PROVIDER: S-EPMC8935717 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA